Context: Overexposure to the essential trace element selenium has been associated with adverse metabolic and cardiovascular outcomes, hypertension, and diabetes. However, dose–response meta-analyses analyzing the effects of selenium administration on the lipid profile in experimental human studies are lacking. Objective: Through a restricted cubic spline regression meta-analysis, the dose–response relation between the dose of selenium administered or blood selenium concentrations at the end of the trials and changes over time in blood lipids, ie, total, high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol, and triglycerides was assessed. Data Sources: Searches were performed on PubMed, Web of Science, Embase, and the Cochrane Library from inception up to January 11, 2025 to identify randomized controlled trials (RCTs) investigating the impact of selenium supplementation on blood lipid profiles among adults. Data Extraction: A total of 27 eligible RCTs that enrolled healthy individuals, pregnant individuals, and participants with specific health conditions were identified and the relevant data was extracted. Data Analysis: Dose–response analysis indicated that selenium administration at and above 200 µg/day decreased HDL and LDL cholesterol and increased triglyceride levels. Blood selenium concentrations at the end of the trial above approximately 150 µg/L were positively associated with triglyceride and LDL cholesterol concentrations, and inversely associated with HDL cholesterol. Inorganic selenium supplementation showed stronger associations than organic selenium. At the lowest levels of baseline intake, selenium supplementation appeared instead to have beneficial effects on the lipid profile, with an overall indication of U-shaped curves, apart from HDL-cholesterol. The adverse effects of selenium were stronger in studies involving healthy participants as compared with unhealthy participants and pregnant females, in those having a longer duration of the intervention, particularly more than 3 months, and in European populations at selenium intake levels of above 300 µg/day. Conclusions: In this dose–response meta-analysis of experimental human studies, an adverse effect of selenium administration on blood lipids at levels around or above the current upper level of intake was observed. Systematic Review Registration: PROSPERO registration No. CRD42022380432.
Background and objectives: Attention deficit hyperactivity disorder (ADHD) is a childhood-onset neurodevelopmental disorder characterized by two dimensions: inattentiveness and hyperactivity/impulsivity. ADHD may be the result of complex interactions between genetic, biological and environmental factors possibly including fluoride exposure. Materials and methods: A literature search was performed on 31 March 2023 in the following databases: PubMed, Embase and Web of Science. We defined the following inclusion criteria according to the PECOS statement: a healthy child and adolescent population (P), fluoride exposure of any type (E), comparison with low or null exposure (C), ADHD spectrum disorder (O), and ecological, cross-sectional, case–control and cohort studies (S). Results: We found eight eligible records corresponding to seven different studies investigating the effect of fluoride exposure on children and adolescents. One study had a cohort design and one a case–control one, while five were cross-sectional. Only three studies applied validated questionnaires for the purpose of ADHD diagnosis. As regards exposure assessment, levels of fluoride in urine and tap water were, respectively used in three and two studies, while two used both. Three studies reported a positive association with ADHD risk, all assessing exposure through fluoride levels. By using urinary fluoride, conversely, a positive correlation with inattention, internalizing symptoms, cognitive and psychosomatic problems was found in three studies, but no relation was found in the other one. Conclusions: The present review suggests that early exposure to fluoride may have neurotoxic effects on neurodevelopment affecting behavioral, cognitive and psychosomatic symptoms related to ADHD diagnosis. However, due to the heterogeneity of the studies included, current evidence does not allow to conclusively confirm that fluoride exposure is specifically linked to ADHD development.
31 August 2022 in Clinical Psychopharmacology and Neuroscience
Mattia Marchi, Giacomo Galli, Gianluca Fiore, Andrew Mackinnon, Giorgio Mattei, Fabrizio Starace, Gian M. Galeazzi. Clin Psychopharmacol Neurosci 2022;20:450-61. https://doi.org/10.9758/cpn.2022.20.3.450
Objective: To gain a better understanding of how long-acting injectable antipsychotic (LAI) therapy is perceived by patients. Methods: A search for qualitative studies has been carried out on PubMed, Google Scholar, PsycINFO and PsycArticles, yielding 11 studies suitable for a review of qualitative studies. The reporting approach chosen was meta-ethnography, following the ENTREQ statement recommendations. Key concepts common to the different studies were extrapolated and then analysed in a systematic and comparative way. Results: Some recurrent issues were associated with LAIs, such as fear of coercion, fear of needles and lack of knowledge about depot therapy. These topics are linked to each other and the patients most concerned about the disadvantages of LAIs are those who are less informed about them, or who have experienced coercion and trauma during hospitalisation. On the other hand, patients who had already received LAIs, and those who had a good therapeutic relationship with their healthcare providers expressed satisfaction with this form of treatment and its continuation. Conclusion: Long-acting injectable antipsychotics are a tool in the management of mental disorders, and a viable alternative to oral medication. Patients show curiosity towards this method of administration, but lack of knowledge is a common finding. Shared decision making about the use of LAIs antipsychotics requires that patients receive accurate information and support for their decision regarding medication.